VIDEO: Treatment regimen appears safe, effective in aggressive non-Hodgkin lymphoma
SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.
Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, told Healio that the research showed that among “heavily pretreated” patients with “aggressive” non-Hodgkin lymphoma, the combination of loncastuximab teserine (Zynlonta, ADC Therapeutics) plus venetoclax (Venclexta, AbbVie) “is relatively well tolerated without a significant increase in toxicity for what you would normally observe with venetoclax alone or with loncastuximab alone.
“In general, it seems like the activity of the combination is higher than what you would see with either drug alone in patients that are heavily pretreated with [chimeric antigen receptor (CAR)] T-cell — many of them were receiving bispecific antibodies — and without increased toxicity,” Caimi added. “So, it is a potential combination to examine further for our patients with indolent as well as aggressive lymphoma.”
Collapse
Healio Interviews